BATEA ONCOLOGY S.L.
Contact information
- Medical devices
- Oncology
- Central nervous system
Batea Oncology is a biotechnological company incorporated in 2024 that investigates and develops new technologies for the treatment of cancer diseases. It arises from the research carried out at the University Hospital and the Health Research Institute of Santiago, with a clear translational approach to respond to unmet clinical needs.
The team combines the clinical approach, which ensures the arrival to patients, with a very wide scientific and researcher base and with demostrated experience in startup creation and management.
As first asset, we have developed a medical device for glioblastoma treatment, the most common brain tumor, for which there are no therapeutic options and in which 5 -year survival is <5%.
Our goal is to change the treatment and response paradigm of these patients, for which we hope to start a pilot clinical trial in 2025.
Our first medical device, GlioHook, is implanted in glioblastoma patients at the time of surgery and acts in a dual way: on the one hand it focuses the residual tumor cells, avoiding their infiltration in the healthy brain, and on the other it sensitizes tumor cells to radiotherapy.
Our in vitro and in vivo results in animal glioblastoma models show that GlioHook is safe that increases survival when combined with radiotherapy.
- Oncology.
- Metastasis.
- Glioblastoma.
- Medical devices.
- Radiotherapy.
- Internacionalization.
- Regulatory framework.
- Research projects.
- Clinical trials.
- Market access.